Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780777 | 0.74 | NAMPT (0.59) | MEN1KMT2ASMN1; SMN2NPC1NAMPT | |
| SCHEMBL3344069 | 0.74 | PARP1 (0.42) | — | |
| SCHEMBL21098369 | 0.74 | SMN1; SMN2 (0.89) | MEN1KMT2ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL10850398 | 0.74 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2NPC1NAMPT | |
| SCHEMBL6571604 | 0.73 | SMN1; SMN2 (0.84) | MEN1KMT2ASMN1; SMN2NPC1NAMPT | |
| Trifluoroacetic Acid SCHEMBL3339735 | 0.72 | PARP1 (0.48) | SMN1; SMN2KDM4EGAARAD52ALDH1A1 | |
| SCHEMBL10853932 | 0.71 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2NPC1NAMPT | |
| SCHEMBL6015763 | 0.71 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2NPC1NAMPT | |
| SCHEMBL3338476 | 0.70 | PARP1 (0.47) | MEN1KMT2ASMN1; SMN2KDM4EGAA | |
| SCHEMBL10822114 | 0.70 | NAMPT (0.71) | MEN1KMT2ASMN1; SMN2NPC1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152180-A1 | 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152180-A1 | 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | PARP1, PARP2, PARP4 | MEN1 3506/4885KMT2A 2729/4885SMN1; SMN2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.